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Evaluation of Cellular-level Haversian Bone Resorption
in Human Hyperparathyroid States
A P r e l i m i n a r y Report

H . M . Frost, M.D.,* A. R. Villanueva, B.S.,** Z. F. Jaworski, M.D.,***
P. Meunier, M.D.t and A. G. Shimizu, M.D.tt
Cellular-level bone resorption was evaluated in 16 patients undergoing renal
dialysis and in two with primary hyperparathyroidism,
by quantitative
histological means using tissue time markers. When averaged over periods greater
than two weeks, the individual osteoclasts in these patients resorbed less bone
in unit time than normal.

This article reports an evaluation
of an index of the speed of cellularlevel haversian bone resorption in
human subjects with naturaUy occurring hyperparathyroid states. Such an
evaluation has relevance for at least
four reasons.
First, direct measurements of this
activity in bone have never been reported before, either in human or in
experimental material;i indeed, some
believe it impossible to measure this
activity in human material.
Second, many assume that parathyroid hormone makes osteoclasts individually "voracious."'-^
Third, humans with naturally occurring metabolic bone disease provide

the actual bone dynamic abnormalities which experimental work must
subsequently explain in detail. Such
patients have usually been iU long
enough by the time of diagnosis and
bone biopsy to provide a reasonably
reliable steady state with respect to
any abnormal bone dynamics that
characterize their disease.*
Fourth, when imbalance between resorption and formation exists for many
months, the bones act as living integrators of this imbalance, showing
progressively enlarging and unambiguous morphological consequences. One
can measure such changes accurately
and directly in bone biopsies, and
given the time factor one can express
them as rates.
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Materials
1) This study includes 16 patients
with chronic renal failure who were
on repeated renal dialysis, and from
whom l l t h rib biopsies were sent to
us by A. G. Shimizu, M.D.; R. G.
Yaworski, M.D.; P. Kenmore, M.D.;
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and J. Pierce, M.D. These 4 women
and 12 men had clinical symptoms of
uremia for an average of 1.47 years,
and they averaged 36.1 years of age.
High levels of circulating parathyroid
hormone (PTH) have been found in
such patients by others.* All 16 of these
patients had clear evidence of renal osteodystrophy, revealed by histological
examination of their l l t h rib biopsies,-*
and most of them had had serum
chemical evidence of azotemia, and
presumably, therefore, had abnormal
bone dynamics for much longer than
their clinical uremic symptoms.
2) Two women in this study had
proven primary hyperparathyroidism,
and yielded l l t h rib biopsies at the
time of removal of their parathyroid
adenoma.
Table I briefly summarizes the case
material.

Methods
1) Labels, Biopsies and Sections:
All patients were given one or more
oral tetracycline bone markers of demethylchlortetracycline in vivo. Biopsy
of the anterior third of the l l t h rib
was subsequendy performed and the
specimen was forwarded to the laboratory in 70% ethanol. At least
six undecalcified, accurately oriented
cross-sections .07mm thick were made
upon receipt of the biopsy and stained
with the Villanueva osteochrome bone
stain, except for one section per case
which was not stained. This was to
ensure by comparison under the fluorescence microscope that the staining
procedures had not eluted and/or obscured the tetracycline labels.'^'
"
2) Rationale: The mathematical,
histological and physiological relations

TABLE

I

Clinical Data on 14 Renal Dialysis Patients

Duration of
Case
Patient's
Symptoms
Number Initials Diagnosis Age Sex before Rib BUN
Serum
Serum
Serum
Alkaline
Biopsy
Creatinine Calcium
Phosphorus Phosphatase
(mos.) Img/lOOmI) (mg/lOOmI) (mg/lOOmI) (mg/lOOmI)
(K.A.U.I
1
CG.
Uremia
30 F
5
146
17.6
10.1
8.96
4.8
2
P.S.
30 F
40
225
21.6
8.0
15.6
8.4
"
3
G.S.
47 M
36
n.a.
n.a.
8.5
8.3
n.a.
4
W.B.
36 M
5
164
24.4
5.0
11.5
12.0
5
LV.
38 F
7
186
28.4
7,4
7.2
10.8
6
W.H.
46 M
25.5
158
22.4
7.8
9.9
10.8
7
E.T.
37 F
13
160
16.8
7.5
7.6
7.2
"
8
R.S.
29 M
11
182
23.0
9.5
14.2
4.8
9
E.Y.
36 M
26
129
24.0
7.5
8.8
9.6
10
B.B.
30
3.5
164
18.0
9.3
8.5
14.6
11
A.L.
4J M
7.5
215
28.0
8.5
13.7
12.0
"
12
J.B.
i?
M
23
145
16.0
4.5
7.45
9.6
13
F.S.
48 fvl
30
103
15.1
9.0
7.:^
16.8
"
14
D.H.
30 M
18.5
134
19.4
.8.0
6.0
9.0
15
P.H.
22 M
12
121
16.7
8.5
7.1
8.6
16
P.M.
33 M
20
163
21.0
8.6
8. 8
10.4
17
L.H.
iOHPTH
42 F
24
21
.6
11.2
2.1
5.0
18
E. R. i° HPTH 63 F
24
15
1.0
12.1
2.0
4.9

The major clinical features of the case material in the present study are summarized.
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which allow determination of cellular
level resorption by quantitative histological means have been outlined elsewhere.Based on the use of a minimum of two tissue time markers for
formation, and on two more for bone
loss or gain, these relations are described next. The basic relation is:
When one sums all bone formation and
resorption over previous time, their
difference equals the amount of bone
present. In a modified derivative form,
the relation becomes: If the mean bone
formation (dF) and resorption (dR)
rates are added up during a disease,
their difference equals the mean rate
of loss or gain (dB) during the disease.
In exactly equivalent symbols:

ply to net bone gain. Therefore dB
is determinate, in histological practice
as well as in theory.
Given values for both dF and dB,
solving equation (1) for dR yields:
dR = dB — dF
(Equation 2)
Now dR represents the bone resorption rate, and in histological terms
this also equals the product of that
fraction of an envelope's surface undergoing resorption at any moment ( R ) ,
times the mean depth of bone eroded
from that fraction in unit time by osteoclasts (Mr).'' Therefore we can
"resolve" dR as the product of the
above two parameters, thus:
dR = R Mr
(Equation 3)
(R), the fractional resorption surface, can also be measured accurately
and directly in bone sections. While
Mr, the depth of bone eroded in unit
time, cannot be so measured, we can
now express it as a unique relation to
other parameters which can be measured directly, by first substituting
equation (3) into ( 2 ) :
R Mr = dB — dF (Equation 4)
and then dividing both sides by R:
— dF (Equation 5)
Mr
R
3) Measurements: To obtain values
for the right hand terms of equation
(5), these measurements of haversian
remodeling were made by methods
outlined in the cited references. The
bone formation rate (dF) in units of
mm- bone formed/mm envelope perimeter/year,'''
and the decimal
fraction of the total haversian perhneter covered by Howship's lacunae
( R ) . " To find dB, the total haversian
perimeters in the sections,and the
intracortical porosities,were measured.
Haversian ^dB: A patient's intra-

dF + dR = dB (Equation 1)
Given meaningful values for dF and
dB, one then solves this equation for
dR. Such values can be obtained by
the following means:
dF, the bone formation rate, can be
measured accurately by two available
means."' " Here, dB represents the
rate of net loss of bone on the haversian envelope during a disease, and
any such loss must progressively increase the intracortical porosity, an
enlargement easily detected and measured by comparing measurements of
this property in biopsies of diseased
patients to comparable samples of
normal persons. Here, the normals reveal the probable status of the patients
before they become ill ("marker" #1
for bone loss), while the patients reveal any cumulative imbalance that
resulted during their disease ("marker"
#2 for bone loss).!'' These differences,
divided by the duration of the disease
over which they developed, become
the mean rate of loss, i.e., dB in
equation ( 1 ) . Converse, arguments ap261
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cortical porosity was subtracted from
his age-comparable norm to obtain the
net change (if any) during his disease,
subject only to the uncertainty due to
normal variation in porosity. One S.D.
variation in this porosity represents an
amount of bone equal to an 8.2%
change in the normal Mr over a period
of 1.47 years, which represents a relatively small uncertainty in the value of
Mr in an individual case. Positive
values of dB imply a deficit, negative
values an excess, of resorption relative
to formation. For each patient this
value was then divided by the duration of his uremic symptoms, to express bone loss or gain as a mean
annual rate. When divided by the
total haversian perimeter, loss or gain
appears as mm^ of compacta/millimeter of haversian envelope/year.
At this point numerical values were
substituted into each term on the right
of equation ( 5 ) , the necessary arithmetic done, and Mr obtained, separately for each case.
4) Normals: Since norms were obtained by similar methods, any syste-

matic errors in the work should affect
both patients and norms equally. Such
errors in any event do not exceed one
part in 20, which constitutes the known
absolute accuracy of this work in our
hands.
Table I I summarizes the data along
with the norms required for comparison.
Results
1) Haversian Radial Resorption
Rate: At .106
.1 mm/year, the
mean Mr of the dialysis group averaged 29.5% of the norm for age 36.1
years. The mean of the two women
with primary hyperparathyroidism
averaged 68% of their mean normal.
The scatter plot in Figure 1 shows the
distribution of Mr values after expressing the value in each patient as a percent of his age-comparable norm.
2) Evaluation of Reliability: Dialysis cases: Equation (5) shows that
Mr decreases inversely proportionally
to R, and directly proportionally to
dF and dB. In the dialysis group (R)
was supernormal in 15 patients (aver-

TA_B_Li; M
Haversian Envelope
Group

Dialysis
16(4)

Comparable
Normal
143(12)

Primary
Hyperparathyroidism
2(-)

Comparable
Normal
81 (9)

Parameter

Units

Fractional Formation Surface (F)

mm/mm

.04 + .1

.16

.04 + .015

Fractional Resorption Surface (R)

mm/mm

. 185 1 .01 .03 + .01

.12

.03 + .01

Rate of bone loss (dB)

-. 0083

-.007

-.0006

Radial Closure Rate (Mj)

mm'/mm/yr
mm/yr

.023 + .02 . 34 + .12

.064

.28 + .1

Radial Resorption Rate (1V1|.)

mm/yr

. 106 i . 1 . 36 i .1

.15

.22 + .07

9

.04 + .015

-.0006

For each patient group, the mean data required to compute the radial resorption rates are
listed. These rates were computed separately from the raw data for each case, so tljc
mean radial resorption rate for a given group will not agree exactly with that which is
computed from the listed mean values of the raw data.
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age 350% of normal), and slightly
subnormal in one patient (90% of
normal), so the group's increase in R is
significant (p.<.001) and greatly exceeds the errors of measurement. dF
was subnormal in 15 patients (average
34% of normal), and normal in one,
so that this depression too is significant
(p.<.001), and it also greatly exceeds
the errors of its measurement. dB was
elevated in 14 and decreased in 2 patients (average net increase equaled
—.009% ) and although small, it differs significantly from the normal value
of —.0005 mmVmm/year (p.<.01),
and exceeds by a factor of three the
errors of its measurement.
Primary hyperparathyroid cases:
In these two women all of the haversian parameters were between one and
two S.D. different from normal in that
direction which lowered the value of
Mr, except the intracortical porosity,
which was 3 S.D. larger than normal in
each, tending to raise the Mr value. In
spite of this, their mean Mr was low,
their increased porosities reflecting
relatively greater depressions of tissuelevel bone formation than of resorption. Although their abnormal changes
were at least 10 times larger than the
errors of measurement, there are too
few of these patients, and then: abnormalities are too small, to achieve
an acceptable level of statistical confidence.
In sum then, the depressed Mr in
the dialysis group is significant, but
due to a limited sample that seen in
the primary hyperparathyroid women
is not. Other factors reenforcing these
conclusions will be given shortly.
It is important to note here a dynamic peculiarity of the analytical system that was employed: It averages Mr

o

00%

4oa

o
o
o A
o
•

A

HAVERSIAN
Figure 1
Scatter plot of haversian radial resorption
rates, normalized to sex, age- and bonecomparable norms. Circles: dialysis cases.
Triangles: primary hyperparathyroid cases.
Squares: secondary hyperparathyroidism.
The single greatly supernormal haversian
value is considered to arise from a greatly
underestimated duration of disease. Nevertheless the value of this case was included
in computing the dialysis group's mean M.value.

over time periods equal to or longer
than the tetracycline labeling interval,
which was approximately two weeks.
Consequently these findings do not rule
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out the possibility that Mr might temporarily reach normal or even supernormal values over much shorter periods of time, although they do make
it very unlikely that the average Mr
over longer periods of time was normal
or supernormal.

200%-^

Discussion
A subnormal radial resorption rate
alone does not reveal the relative activity of the typical individual osteoclast, that is whether it is supernormal,
normal or subnormal." However,
other information permits these deductions :
First, the fractional resorption surface (R in Table I I ) was greatly increased in these cases, similar to findings noted by others in similar material.17-19

Second, and somewhat unexpectedly,
the tissue-level haversian bone resorption rates were subnormal in the
dialysis group, as satisfaction of equation (2) with the data shown (p.<.01)
and as was predicted by others.-" It
was normal in the two women with
primary hyperparathyroidism (Fig 2).

100%--^A-^

0-

Haversion
Resorption Rote
Figure 2

Tissue-level haversian bone resorption rates
of each case, normalized to age- and bonecomparable norms. Circles: dialysis cases.
Triangles: primary hyperparathyroidism.
The three greatly supernormal values are
probably spurious, and attributable to underestimating durations of bone disease
which, based on clinical symptoms of uremia, were .29, .42 and .47 years. By serum
chemical tests all three cases had had
azotemia for more than two years, and
recomputation on that basis would have
brought each of these rates below normal.

Third, multiple observers consistendy found osteoclasts in greatly increased numbers in these states."^' -When more osteoclasts lie on an enlarged resorption surface, yet resorb
less bone, in terms both of quantity
resorbed and of depth eroded in unit
time, then individual osteoclasts resorb
bone at subnormal average speed. The
real question then is not whether this
is so but rather: how much so?
Two further points enhance the reliability of the above conclusion:

evidence of azotemia longer than they
had clinical symptoms of uremia, so
the estimates of the durations of their
bone diseases are probably conservative; this caused the computed Mr
values to be higher than the true ones.
Two, some of the increased porosity
which was involved in computing dB,
and which tends to raise the computed
values of Mr, represents a purely tem-

One, these cases had serum chemical
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porary and nonprogressive bone loss
which always accompanies increased
numbers of bone resorbing and forming centers (average in both of the
present groups: 3.5 x normal), each
of which adds a temporary deficit of
approximately .003 mm- of bone to the
envelope on which it lies. This represents a phase lag poo/." Because no
correction was made for it, this too
caused the computed values of Mr to
be higher than their true ones.
In other words, these data define
an upper bound of Mr; the true values

lie somewhere below. For these reasons
(as well as others),-^ the depressed Mr
in the dialysis group should not arise
from sampling effects or from measuring errors.
Clearly we need independent confirmation of these results, particularly
in more cases of primary hyperparathyroidism. Clearly too the temptation
to ascribe these findings to the effect
of parathyroid hormone alone must be
resisted, for many other existing factors
in each group could have caused them.
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